Novocure Limited · NASDAQ:NVCR
Novocure — Q1 2026 Earnings Presentation
12 slides from Novocure's earnings presentation, Apr 30, 2026
Slide 1: Q1 2026 Quarterly Earnings
Q1 2026 Quarterly Earnings Thursday, April 30, 2026 © 2026 Novocu re GmbH 1
Slide 2: Forward-looking statements
forward - looking statements In addition to historical facts or statements of current condition, this presentation may contain forward - looking statements. Fo rward - looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding ant
Slide 3: Strategic roadmap balancing growth and profitability
strategic roadmap balancing growth and profitability drive scale advance pursue adoption portfolio innovation profitability in approved through new through clinical to fuel growth and indications indication launches and product shareholder value development © 2026 Novocu re GmbH 3
Slide 4: Key catalysts anticipated in 2026
key catalysts anticipated in 2026 ✓ Q1 : Release topline data from Phase 2 PANOVA - 4 trial (metastatic PDAC) CLINICAL Q2 : Release topline data from Phase 3 TRIDENT trial (GBM) Q4 : Complete enrollment in Phase 3 KEYNOTE D58 trial (GBM) ✓ Q1 : Launch Optune Pax for pancreatic cancer in the U.S. COM
Slide 5: Optune Pax: launch ongoing, promising early signals
Optune Pax: launch ongoing, promising early signals PHYSICIANS ARE EAGER FOR EFFECTIVE, LOW - TOXICITY OPTIONS TO TREAT PDAC CERTIFICATIONS PRESCRIPTIONS PATIENT ACTIVE COMPLETED RECEIVED STARTS PATIENTS 868 169 90 83 All statistics are as of March 31, 2026. © 2026 Novocu re GmbH 5
Slide 6: Q1 2026 select financials
Q1 2026 select financials U.S. DOLLARS IN MILLIONS Q1 2026 Q1 2025 Net revenues $ 174.1 $ 155.0 Cost of revenues 38.9 38.5 Gross profit 135.1 116.5 Research, development and clinical expenses 58.3 53.8 Sales and marketing 58.4 55.8 General and administrative 85.9 44.8 Total operating costs and expen
Slide 7: 2026 net revenue & adjusted EBITDA guidance
2026 net revenue & adjusted EBITDA guidance FY 2026 net revenue KEY ASSUMPTIONS $690M – $710M • Optune Gio net revenue: (previous: $675M – $705M) Mid- single digit growth from FY 2025 • Optune Lua, Optune Pax net revenue : $15M – $25M anticipated collective contribution • Gross margin : FY 2026 Adj.
Slide 8: Together with our patients, we strive to extend survival in some of the most aggressive forms of cancer
actor portrayal together with our patients, we strive to extend survival in some of the most aggressive forms of cancer © 2026 Novocu re GmbH 8
Slide 9: Adjusted EBITDA reconciliation
adjusted EBITDA reconciliation Adjusted EBITDA is a non - GAAP measurement of earnings before interest, taxes, depreciation, amortization and share - based compens ation. We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the
Slide 10: Optune Gio, Optune Lua and Optune Pax indications for use
Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information INDICATIONS FOR USE • Optune Gio ® is intended as a treatment for adult patients (22 years of age or older) with histologically confirmed glioblastoma multiform e (GBM). • Optune Gio with temozolomide i
Slide 11: Optune Gio, Optune Lua and Optune Pax indications for use: warnings and precautions
Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information WARNINGS AND PRECAUTIONS • Optune Gio, Optune Lua, and Optune Pax can only be prescribed by a healthcare provider that has completed the required certif ica tion training provided by Novocure ® (the dev
Slide 12: Optune Gio, Optune Lua and Optune Pax indications for use: warnings and precautions (cont'd)
Optune Gio ® , Optune Lua ® and Optune Pax ® indications for use and important safety information WARNINGS AND PRECAUTIONS (CONT’D) • The most common ( ≥10%) adverse events involving Optune Pax concomitant with gemcitabine and nab - paclitaxel were neutropenia, ane mia, thrombocytopenia, leukopenia,